Efavirenz Concentrations in HIV-Infected Patients With and Without Viral Hepatitis

• Autor(es): Pereira, SA ; Caixas, U ; Branco, T ; Germano, I ; Lampreia, F ; Papoila, AL ; Monteiro, E
• Data: 2008
• Identificador Persistente: http://hdl.handle.net/10400.17/1776
• Origem: Repositório do Centro Hospitalar de Lisboa Central, EPE
• Assunto(s): CHLC MED; Doenças Hepáticas; Inibidores de Transcriptase Reversa; Projectos Piloto; Índice de Gravidade da Doença; Resultado de Tratamento; Carga Viral; Infecções Oportunistas Relacionadas com a SIDA; Benzoxazinas; Contagem de Linfócito CD4; Estudos de Casos e Controles; Evolução da Doença; Relação Dose-Resposta a Medicamento; Monitorização de Medicamentos; Estudos de Follow-Up; Infecção por HIV; Hepatite B Crónica; Hepatite C Crónica; Metabolismo
• Tipo de Documento: Artigo
• Idioma: Inglês

Descrição

AIMS: Data on efavirenz in HIV/viral hepatitis co-infected patients is non-consensual, probably due to liver function heterogeneity in the patients included. METHODS: A case control study was performed on 27 HIV-infected patients, with controlled and homogenous markers of hepatic function, either mono-infected or co-infected with HBV/HCV, to ascertain the influence of viral hepatitis on efavirenz concentrations over a 2-year follow-up period. RESULTS: No differences were found in efavirenz concentrations between groups both during and at the end of the follow-up period: control (2.43 +/- 1.91 mg l(-1)) vs. co-infected individuals (2.37 +/- 0.37 mg l(-1)). CONCLUSION: It was concluded that HBV/HCV infections in themselves do not predispose to an overexposure to efavirenz.